SEC Company Response from Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838) — Mar 31, 2020
Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)
Date: March 31, 2020 · CIK: 0001106838 · Accession: 0001493152-20-005423
AI Filing Summary & Sentiment
File numbers found in text: 333-237354
Show Raw Text
CORRESP
1
filename1.htm
CHANTICLEER
HOLDINGS, INC.
7621
Little Avenue, Suite 414
Charlotte,
NC 28226
(704)
366-5122
March
31, 2020
VIA
EDGAR CORRESPONDENCE
Katherine
Bagley
Office
of Trade and Services
Division
of Corporate Finance
United
States Securities Exchange Commission
Washington
D.C. 20549
Re:
Chanticleer Holdings, Inc.
Registration
Statement on Form S-3
Filed
March 24, 2020
File
No. 333-237354 (“Registration Statement”)
Dear
Ms. Bagley:
Pursuant
to Rule 460 and Rule 461 under the Securities Act of 1933, as amended, Chanticleer Holdings, Inc., a Delaware corporation (the
“Company”), hereby requests that the effective date of the above referenced Registration Statement be accelerated
so that it will become effective at 10 a.m. Eastern time on Thursday, April 2, 2020, or as soon thereafter as practicable.
The
Company acknowledges that:
●
should
the Securities and Exchange Commission
(“Commission”) or the staff,
acting
pursuant to
delegated authority,
declare the filing effective,
it does not foreclose
the Commission from
taking any
action
with respect to the
filing;
●
the
action of the Commission
or the staff, acting
pursuant to
delegated
authority,
in declaring
the filing effective,
does not relieve
the Company
from its full responsibility
for the adequacy
and accuracy
of the disclosure in the
filing;
and
●
the
Company may
not assert staff
comments
and the declaration
of effectiveness
as a defense in any
proceeding initiated
by the Commission
or any person
under the federal
securities
laws of the United States.
Very
truly yours,
CHANTICLEER
HOLDINGS, INC.,
a
Delaware corporation
/s/
Michael D. Pruitt
By:
Michael
D. Pruitt
Its:
Chief
Executive Officer and Chairman